Literature DB >> 29123961

Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade.

Alejandro López-Soto1, Segundo Gonzalez1, Lorenzo Galluzzi2,3,4.   

Abstract

Entities:  

Keywords:  CTLA4; MICB; NK cells; PD-1; immune checkpoint blockers; pembrolizumab

Year:  2017        PMID： 29123961      PMCID： PMC5665085          DOI： 10.1080/2162402X.2017.1346766

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


× No keyword cloud information.
  18 in total

1.  Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Authors:  Cristina Maccalli; Diana Giannarelli; Filippo Capocefalo; Lorenzo Pilla; Ester Fonsatti; Anna Maria Di Giacomo; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

Review 2.  DNA Damage in Stem Cells.

Authors:  Ilio Vitale; Gwenola Manic; Ruggero De Maria; Guido Kroemer; Lorenzo Galluzzi
Journal:  Mol Cell       Date:  2017-05-04       Impact factor: 17.970

Review 3.  NKG2D signaling in cancer immunosurveillance.

Authors:  Alejandro López-Soto; Leticia Huergo-Zapico; Andrea Acebes-Huerta; Mónica Villa-Alvarez; Segundo Gonzalez
Journal:  Int J Cancer       Date:  2014-03-03       Impact factor: 7.396

Review 4.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

5.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.

Authors:  Eliezer M Van Allen; Diana Miao; Bastian Schilling; Sachet A Shukla; Christian Blank; Lisa Zimmer; Antje Sucker; Uwe Hillen; Marnix H Geukes Foppen; Simone M Goldinger; Jochen Utikal; Jessica C Hassel; Benjamin Weide; Katharina C Kaehler; Carmen Loquai; Peter Mohr; Ralf Gutzmer; Reinhard Dummer; Stacey Gabriel; Catherine J Wu; Dirk Schadendorf; Levi A Garraway
Journal:  Science       Date:  2015-09-10       Impact factor: 47.728

Review 6.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

7.  Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy.

Authors:  Jianjun Gao; Lewis Zhichang Shi; Hao Zhao; Jianfeng Chen; Liangwen Xiong; Qiuming He; Tenghui Chen; Jason Roszik; Chantale Bernatchez; Scott E Woodman; Pei-Ling Chen; Patrick Hwu; James P Allison; Andrew Futreal; Jennifer A Wargo; Padmanee Sharma
Journal:  Cell       Date:  2016-09-22       Impact factor: 41.582

8.  Antibody targeting soluble NKG2D ligand sMIC refuels and invigorates the endogenous immune system to fight cancer.

Authors:  Jennifer Wu
Journal:  Oncoimmunology       Date:  2015-10-29       Impact factor: 8.110

9.  ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing.

Authors:  Maria Raffaella Zocchi; Caterina Camodeca; Elisa Nuti; Armando Rossello; Roberta Venè; Francesca Tosetti; Irene Dapino; Delfina Costa; Alessandra Musso; Alessandro Poggi
Journal:  Oncoimmunology       Date:  2015-12-29       Impact factor: 8.110

10.  Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.

Authors:  Jingyu Zhang; Dai Liu; Guangfu Li; Kevin F Staveley-O'Carroll; Julie N Graff; Zihai Li; Jennifer D Wu
Journal:  Sci Adv       Date:  2017-05-17       Impact factor: 14.136
View more
  7 in total

Review 1.  Trial Watch: Toll-like receptor agonists in cancer immunotherapy.

Authors:  Melody Smith; Elena García-Martínez; Michael R Pitter; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-10-11       Impact factor: 8.110

Review 2.  Emerging biomarkers for the combination of radiotherapy and immune checkpoint blockers.

Authors:  Claire Lhuillier; Claire Vanpouille-Box; Lorenzo Galluzzi; Silvia Chiara Formenti; Sandra Demaria
Journal:  Semin Cancer Biol       Date:  2017-12-16       Impact factor: 15.707

Review 3.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

Review 4.  Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?

Authors:  Vicenç Ruiz de Porras; Juan Carlos Pardo; Lucia Notario; Olatz Etxaniz; Albert Font
Journal:  Int J Mol Sci       Date:  2021-04-29       Impact factor: 5.923

Review 5.  Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer.

Authors:  Ofek Mussafi; Jie Mei; Wenjun Mao; Yuan Wan
Journal:  Front Oncol       Date:  2022-08-17       Impact factor: 5.738

6.  Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.

Authors:  Fahmin Basher; Payal Dhar; Xin Wang; Derek A Wainwright; Bin Zhang; Jeffrey Sosman; Zhe Ji; Jennifer D Wu
Journal:  J Hematol Oncol       Date:  2020-06-09       Impact factor: 17.388

7.  Antibody targeting tumor-derived soluble NKG2D ligand sMIC provides dual co-stimulation of CD8 T cells and enables sMIC+ tumors respond to PD1/PD-L1 blockade therapy.

Authors:  Jinyu Zhang; Pablo Saenz-Lopez Larrocha; Bin Zhang; Derek Wainwright; Payal Dhar; Jennifer D Wu
Journal:  J Immunother Cancer       Date:  2019-08-26       Impact factor: 13.751
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.